Blackberry and NantHealth have announced the launch of a clinical genome browser for Blackberry’s Passport device.

Blackberry have announced that they will launch a clinical genome browser early next year in partnership with NantHealth. The browser will be HIPPA-compliant and will allow oncologists to quickly identify genomic biomarkers for targeted treatment.

In a statement, NantHealth CEO, Patrick Soon-Shiong said “The proprietary NantOmics Cancer Genome Browser enables clinicians for the first time to investigate a tumor genome from the full three billion bases down to the single-base level in real-time, thanks to the power of the NantOmics supercomputing infrastructure. This integrates with NantHealth’s treatment protocols to individual patients based on their genomic signature.”

Following the collapse of Blackberry’s consumer market share, the company have been focusing on critical communications markets. Their secure infrastructure has been particularly useful in public safety, and healthcare. If successful, this could be helpful step towards large scale integration of genomic technology into the clinical setting. Price and ease of use will strongly influence uptake of the platform. One of the criticisms of existing healthcare analytics platforms is the, at times, confusing user interface. The NantOmics Cancer Genome Browser is expected to be demonstrated at the Consumer Electronics Show in January.